Enzo Biochem Share Holder Equity 2010-2022 | ENZ

Enzo Biochem share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Enzo Biochem Annual Share Holder Equity
(Millions of US $)
2021 $69
2020 $58
2019 $86
2018 $81
2017 $89
2016 $90
2015 $43
2014 $37
2013 $34
2012 $49
2011 $89
2010 $97
2009 $117
Enzo Biochem Quarterly Share Holder Equity
(Millions of US $)
2022-04-30 $62
2022-01-31 $65
2021-10-31 $67
2021-07-31 $69
2021-04-30 $65
2021-01-31 $62
2020-10-31 $59
2020-07-31 $58
2020-04-30 $62
2020-01-31 $71
2019-10-31 $78
2019-07-31 $86
2019-04-30 $91
2019-01-31 $67
2018-10-31 $76
2018-07-31 $81
2018-04-30 $86
2018-01-31 $88
2017-10-31 $89
2017-07-31 $89
2017-04-30 $89
2017-01-31 $88
2016-10-31 $88
2016-07-31 $90
2016-04-30 $53
2016-01-31 $54
2015-10-31 $47
2015-07-31 $43
2015-04-30 $34
2015-01-31 $35
2014-10-31 $36
2014-07-31 $37
2014-04-30 $38
2014-01-31 $32
2013-10-31 $33
2013-07-31 $34
2013-04-30 $35
2013-01-31 $40
2012-10-31 $46
2012-07-31 $49
2012-04-30 $76
2012-01-31 $79
2011-10-31 $83
2011-07-31 $89
2011-04-30 $92
2011-01-31 $92
2010-10-31 $97
2010-07-31 $97
2010-04-30 $102
2010-01-31 $105
2009-10-31 $116
2009-07-31 $117
2009-04-30 $120
2009-01-31 $123
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.105B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00